OpenURL Connection Search

Select item for more details and to access through your institution.

Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials.
Published in:
Pharmaceuticals (14248247), 2024, v. 17, n. 4, p. 481, doi. 10.3390/ph17040481
By:
- Krishnan, Anitha;
- Callanan, David G.;
- Sendra, Victor G.;
- Lad, Amit;
- Christian, Sunny;
- Earla, Ravinder;
- Khanehzar, Ali;
- Tolentino, Andrew J.;
- Vailoces, Valory Anne Sarmiento;
- Greene, Michelle K.;
- Scott, Christopher J.;
- Kunimoto, Derek Y.;
- Hassan, Tarek S.;
- Genead, Mohamed A.;
- Tolentino, Michael J.
Publication type:
Article
A novel RCE1 isoform is required for H-Ras plasma membrane localization and is regulated by USP17.
Published in:
Biochemical Journal, 2014, v. 457, n. 2, p. 289, doi. 10.1042/BJ20131213
By:
- JAWORSKI, Jakub;
- GOVENDER, Ureshnie;
- McFARLANE, Cheryl;
- DE LA VEGA, Michelle;
- GREENE, Michelle K.;
- RAWLINGS, Neil D.;
- JOHNSTON, James A.;
- SCOTT, Christopher J.;
- BURROWS, James F.
Publication type:
Article
Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.
Published in:
Cancers, 2021, v. 13, n. 24, p. 6175, doi. 10.3390/cancers13246175
By:
- Greene, Michelle K.;
- Johnston, Michael C.;
- Scott, Christopher J.
Publication type:
Article
PolySialic acid-nanoparticles inhibit macrophage mediated inflammation through Siglec agonism: a potential treatment for age related macular degeneration.
Published in:
Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1237016
By:
- Krishnan, Anitha;
- Sendra, Victor G.;
- Patel, Diyan;
- Lad, Amit;
- Greene, Michelle K.;
- Smyth, Peter;
- Gallaher, Samantha A.;
- Herron, Úna M.;
- Scott, Christopher J.;
- Genead, Mohamed;
- Tolentino, Michael
Publication type:
Article
Targeting Siglecs with a sialic acid–decorated nanoparticle abrogates inflammation.
Published in:
Science Translational Medicine, 2015, v. 7, n. 303, p. 1, doi. 10.1126/scitranslmed.aab3459
By:
- Spence, Shaun;
- Greene, Michelle K.;
- Fay, François;
- Hams, Emily;
- Saunders, Sean P.;
- Hamid, Umar;
- Fitzgerald, Marianne;
- Beck, Jonathan;
- Bains, Baljinder K.;
- Smyth, Peter;
- Themistou, Efrosyni;
- Small, Donna M.;
- Schmid, Daniela;
- O’Kane, Cecilia M.;
- Fitzgerald, Denise C.;
- Abdelghany, Sharif M.;
- Johnston, James A.;
- Fallon, Padraic G.;
- Burrows, James F.;
- McAuley, Daniel F.
Publication type:
Article
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
Published in:
2020
By:
- Greene, Michelle K.;
- Chen, Ting;
- Robinson, Eifion;
- Straubinger, Ninfa L.;
- Minx, Charlene;
- Chan, Darren K. W.;
- Wang, Jun;
- Burrows, James F.;
- Van Schaeybroeck, Sandra;
- Baker, James R.;
- Caddick, Stephen;
- Longley, Daniel B.;
- Mager, Donald E.;
- Straubinger, Robert M.;
- Chudasama, Vijay;
- Scott, Christopher J.
Publication type:
journal article

Found: 6

Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials.

A novel RCE1 isoform is required for H-Ras plasma membrane localization and is regulated by USP17.

Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.

PolySialic acid-nanoparticles inhibit macrophage mediated inflammation through Siglec agonism: a potential treatment for age related macular degeneration.

Targeting Siglecs with a sialic acid–decorated nanoparticle abrogates inflammation.

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.